BMJ  2003;327:1222-1225 (22 November), doi:10.1136/bmj.327.7425.1222

Education and debate

Joining the DoTS: new approach to classifying adverse drug reactions

¹ University Department of Clinical Pharmacology, Radcliffe Infirmary, Oxford OX2 6HE, ² West Midlands Centre for Adverse Drug Reaction Reporting, City Hospital, Birmingham B18 7QH, UK

A new classification system for adverse drug reactions based on time course and susceptibility as well as dose responsiveness should improve drug development and management of adverse reactions

The first 150 words of the full text of this article appear below.

The pharmacological classification of adverse drug reactions whose causality has been established currently rests on the perceived dose dependence and predictability of the adverse reaction. It is based on a proposal of Rawlins and Thompson, prefigured by others (see table A on bmj.com), to classify adverse drug reactions into two types¹: type A reactions, dose dependent and predictable from the known pharmacology of the drug; and type B reactions, not dose dependent and unpredictable.² This classification is simple; it helps drug regulation because prelicensing studies can reveal type A reactions,³ and it predicts that dose titration will reduce the risk of some reactions. However, it is sometimes difficult or impossible to assign a reaction to one type. For example, dose dependent (type A) nausea and vomiting due to erythromycin could also be classified as type B because it is not pharmacologically predictable.

Furthermore, other types of adverse reactions are . . . [Full text of this article]

-->
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Communicating information about drug safety

R E Ferner and J K Aronson
BMJ 2006 333: 143-145. [Full Text] [PDF]

Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine

Sarah E McDowell, Jamie J Coleman, and R E Ferner
BMJ 2006 332: 1177-1181. [Abstract] [Full Text] [PDF]

Classification of drug reactions is inadequate
BMJ 2003 327: 0. [Full Text]

Monitoring drug treatment

Munir Pirmohamed and Robin E Ferner
BMJ 2003 327: 1179-1181. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Singh, S., Loke, Y. K., Furberg, C. D. (2007). Thiazolidinediones and Heart Failure: A teleo-analysis. Diabetes Care 30: 2148-2153 [Abstract] [Full text]  
• Ferner, R E, Aronson, J K (2006). Communicating information about drug safety.. BMJ 333: 143-145 [Full text]  
• McDowell, S. E, Coleman, J. J, Ferner, R E (2006). Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 332: 1177-1181 [Abstract] [Full text]  
• Morcos, S K (2005). Acute serious and fatal reactions to contrast media: our current understanding. Br. J. Radiol. 78: 686-693 [Abstract] [Full text]  
• Glasziou, P., Irwig, L., Mant, D. (2005). Monitoring in chronic disease: a rational approach. BMJ 330: 644-648 [Full text]  
• Loke, Y. K. (2004). Assessing the benefit-harm balance at the bedside. BMJ 329: 7-8 [Full text]  
• Stricker, B. H., Psaty, B. M (2004). Detection, verification, and quantification of adverse drug reactions. BMJ 329: 44-47 [Full text]  
• Aronson, J. (2004). HARMful reactions. BMJ 328: 1173-1173 [Full text]  

Rapid Responses:

Read all Rapid Responses

Where does the patient come into this?

Julie A Burgess
bmj.com, 21 Nov 2003 [Full text]

Amendment of previous rapid response

Julie A Burgess
bmj.com, 27 Nov 2003 [Full text]

Online poll

Find out more here>> and here>>